Pain Therapeutics and King present remoxy Phase III data

Data presented at the world pain congress show Pain Therapeutic/Kings oxycodoen product REMOXY to provide effective around-the-clock analgesia

Euroscreen sign agreement with Phoenix for Chemerin and F2L products

Euroscreen has signed an agreement with Phoenix Pharmaceuticals giving access to Chemerin and F2L patent rights. Financial details of this Agreement were not disclosed.

Merck publish series of Nicotinic Acid Receptor GPR109A Agonists

Merck have published a paper on the molecular modeling aided design of Nicotinic Acid Receptor GPR109A Agonists

Merck publish series of NPY Y5 receptor antagonists

Merck have published a series of trans -2-[3-oxospiro[isobenzofuran-1(3H),1’-cyclohexan]-4’-yl]benzimidazole NPY Y5 receptor antagonists

Seretide®/Advair treatment effective in COPD

Study results show that treatment with Seretide/Advair (salmeterol/fluticasone propionate ) slows the progression of Chronic Obstructive Pulmonary Disease (COPD) by lowering a patient’s rate of lung function decline compared with those receiving placebo.

FDA grants priority review to Pain Therapeutics REMOXY

Pain Therapeutics have announced thats its NDA for REMOXY was accepted and granted Priority Review by the US FDA.

FDA Approve Dopamine Antagonist Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington’s disease

US FDA has approved Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington’s disease.

Neurogen publish series of Bradykinin B1 Receptor Antagonists

Neurogen have published a series of 1-Benzylbenzimidazole  B1 Receptor Antagonists

Merck (Banyu) publish series of NPY Y5 receptor antagonists

Merck (Banyu) have publsihed a series of 2-{3-oxospiro[isobenzofuran-1(3H),4’-piperidin]-1’-yl}benzimidazole derivative NPY Y5 receptor antagonists

GSK publish series of Tricyclic Azepine derivative 5HT6 antagonists

GSK have published a  series of Tricyclic Azepine derivative 5HT6 antagonists